Rexahn Pharmaceuticals, Inc. Recap

What is your opinion of Rexahn Pharmaceuticals, Inc.?

Rexahn Pharmaceuticals, Inc.

AMEX:RNN - Jul. 5th 5:25pm

$ 0.605 -0.006 (-0.98%)

Shares of Rexahn Pharmaceuticals, Inc. – a $108.4 million market cap Biotechnology & Medical Research company – have fallen -0.98 percent to $0.605 as of 8:01 PM. With the current share price, Rexahn Pharmaceuticals, Inc. has a P/E Ratio of 0.00.

Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for cancer and other medical needs. The Company has three clinical stage drug candidates in active development: Archexin, a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance; RX-3117, a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including colon, lung and pancreatic cancer, and Supinoxin (RX-5902), a small molecule that inhibits the phosphorylation of p68, which is expressed in cancer cells, but not in normal cells, results in up-regulation of cancer-related genes and a subsequent proliferation or tumor growth of cancer cells. The Company also has two drug candidates in pre-clinical development: Archexin-Nano and RX-21101.

Find out more about Rexahn Pharmaceuticals, Inc..


Rexahn Pharmaceuticals, Inc. Hit a 52-week Low

Rexahn Pharmaceuticals, Inc. (AMEX:RNN) hit a 52-week share price low of $0.6022.

ROCKVILLE, MD | 6 days ago

Financials
Rexahn Pharmaceuticals, Inc.